Detection of Minimal Residual Disease Post-prostatectomy
ConditionProstate Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18+
SponsorRadboud University Medical Center
About this trial
The clinical objective for this pilot study is to determine whether minimal residual disease (MRD) detection in high-risk prostate cancer, utilizing a custom-made prostate-specific circulating tumor DNA (ctDNA) panel, may lead to more optimal prediction of disease recurrence following radical prostatectomy.
Eligibility criteria
Qualifiers
Male aged 18 years or older;
High-risk localized prostate cancer, with PSA level >20 ng/mL, Gleason score 8-10 (ISUP grade 4/5) at prostate biopsies, or iT3a (based on multi-parametric MRI of the prostate); or
High-risk locally advanced prostate cancer, having any PSA level, any Gleason score/ISUP grade, iT3b-4 (based on multi-parametric MRI of the prostate) or iN1 (based on PSMA PET/CT imaging);
Scheduled for robot-assisted radical prostatectomy;
Disqualifiers
Relevant contra-indications that may limit clinical follow-up or blood collection, as assessed by the including physician.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
50 Participants
are grouped into 1 trial groupSponsors and collaborators
Radboud University Medical Center
Lead sponsor
Catharina Ziekenhuis Eindhoven
Collaborator
Canisius-Wilhelmina Hospital
Collaborator
Maxima Medical Center
Collaborator
Source ClinicalTrials.gov